About Us

Who is Sanguina?

Our CEO and founder Erika, and her business partner, Rob, are just two of more than 1.62 billion people worldwide who struggle with anemia, the most common blood disorder.

Their personal battles inspired them to develop affordable and accessible products for regular anemia screening, so people like them could be proactive about their health.

A Brief History of Sanguina

Georgia Roots

Then-Georgia Tech student Erika Tyburski partners with Dr. Wilbur Lam for a senior design project for instant anemia screening. It’s there she meets Rob Mannino.

Award-Winning Ideas

In this year, Erika and Rob launch the first AnemoCheck test prototype, win second place at the Georgia Tech Inventure Prize contest, first at the Georgia Tech Ideas to Serve, and secure their first grant.

Sanguina Is A Company

AnemoCheck is written about in The Journal of Clinical Investigation, and Sanguina officially becomes a company.

FDA Approval

The Food and Drug Administration approves first-generation AnemoCheck for clinical use.

International Patents

AnemoCheck/AnemoCheck Home technology is granted a utility/method patent in the U.S., Europe, and Japan.

Funding Growth

Sanguina secures $2.3 million in seed funding.

AnemoCheck Launches

In December 2021, AnemoCheck becomes available on Google Play and iOS App Stores in the United States.

Premium Subscription Offered

In December 2022, the AnemoCheck Premium Subscription launches featuring MyMobile, your unique algorithm with 50% more accurate results.

AnemoCheck Home FDA Approval

The Food and Drug Administration approves AnemoCheck Home, the only FDA-cleared home anemia test with instant results.

Georgia Roots
Award-Winning Ideas
Sanguina Is A Company
FDA Approval
International Patents
Funding Growth
AnemoCheck Launches
Premium Subscription Offered
AnemoCheck Home FDA Approval